Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial
PaperCitations, authors & open-access status
Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 73 citations, 2022 year and closed oa status.
73
Citations
2022
Year
closed
OA Status